Our daily news digest will keep you up to date with engineering, science and technology news, Monday to Saturday.
By subscribing, you agree to our Terms of Use and Policies You may unsubscribe at any time.
Researchers from Weill Cornell Medicine and Medical Center have found ‘real-world evidence’ of nasal spray’s effectiveness.
The experimental drug Etripamil makes up the drug. Doctors use it to treat abnormal heart rhythms, also called arrhythmia.
According to a statement by Weill Cornell Medicine, a clinical trial led by the institution’s investigators showed promising results.
That is, patients could safely administer the nasal spray at home without a physician’s supervision.
They successfully treated repeat episodes of a condition that causes rapid abnormal heart rhythms.
Nasal spray calcium-channel blocker
Milestone Pharmaceuticals, the company that sponsored the clinical trial, developed the nasal spray calcium channel blocker.
They have been leading the development of etripamil as a potential treatment for paroxysmal supraventricular tachycardia (PSVT) episodes.
The spray …